Status:

ACTIVE_NOT_RECRUITING

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2

Lead Sponsor:

Alkermes, Inc.

Conditions:

Narcolepsy Type 2

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.

Eligibility Criteria

Inclusion

  • 18-70 years of age
  • Has a BMI ≥18 and ≤40 kg/m2
  • Meets the diagnostic criteria of Narcolepsy type 2 according to ICSD-3-TR guidelines.
  • Additionally, meets the following criteria:
  • Has residual excessive daytime sleepiness
  • Is willing and able to discontinue any medications prescribed for the management of narcolepsy symptoms for at least 14 days and for the duration of study
  • Is willing to adhere to additional protocol requirements

Exclusion

  • Significant comorbid medical conditions, including other sleep, cardiovascular, psychiatric, hepatic or other disorders may be exclusionary; eligibility will be determined on an individual basis by the study investigator
  • Is currently pregnant, breastfeeding, or planning to become pregnant during the study
  • Is currently enrolled in another clinical study (other than the parent study) or used any investigational drug or device within 30 days prior to Screening

Key Trial Info

Start Date :

July 26 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2025

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT06555783

Start Date

July 26 2024

End Date

November 1 2025

Last Update

September 24 2025

Active Locations (47)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 12 (47 locations)

1

Alkermes Investigator Site

Little Rock, Arkansas, United States, 72211

2

Alkermes Investigator Site

Los Angeles, California, United States, 90025

3

Alkermes Investigator Site

Redwood City, California, United States, 94063

4

Alkermes Investigator Site

San Francisco, California, United States, 94143